Mapping Cerebral Blood Flow Schizophrenia Alterations Across Clinical Stages

Understanding the pathophysiological progression of psychotic illnesses requires investigating brain structure and function across multiple biological scales. In psychiatric neuroscience, evaluating cerebral blood flow schizophrenia patterns provides critical insights into functional microvascular and metabolic states. Functional brain changes emerge well before the onset of overt schizophrenia spectrum disorders. In particular, young individuals meeting criteria for clinical high risk for psychosis already exhibit demonstrable hemodynamic perturbations. However, clinicians and researchers have long struggled to identify the precise cellular and molecular drivers behind these macroscopic vascular changes. A landmark study published in Biological Psychiatry has bridged this knowledge gap by integrating multimodal neuroimaging with spatial transcriptomics and neurotransmitter density atlases. By mapping regional perfusion abnormalities to underlying genetic transcripts and receptor distributions, researchers have uncovered shared and distinct mechanisms underlying disease progression. Consequently, these findings reshape our understanding of early psychotic illness from macroscopic dysconnectivity to defined neurochemical and neurovascular anomalies. Clinicians can now contextualize hemodynamic variations through specific cellular pathways, providing renewed optimism for targeted therapeutic strategies.

Multiscale Methodology: Merging Neuroimaging, Transcriptomics, and Receptor Atlases

To characterize the biological basis of hemodynamic dysfunction, the research team analyzed regional cerebral blood flow data across 425 participants. Specifically, the cohort comprised 122 patients diagnosed with schizophrenia spectrum disorders matched against 116 healthy controls. In addition, the investigators examined 129 individuals identified as clinical high risk for psychosis alongside 58 healthy control subjects. The investigators acquired brainwide arterial spin labeling perfusion maps to establish robust case-control contrast profiles. Subsequently, they integrated these macroscopic perfusion phenotypes with transcriptomic expression profiles covering 17,205 genes derived from the Allen Human Brain Atlas. Furthermore, the team aligned the neuroimaging data with normative positron emission tomography and single-photon emission computed tomography atlases. These molecular atlases encompassed 19 distinct neurotransmitter receptors and transporters characterized across 1,074 healthy volunteers. Dominance analysis and advanced spatial permutation testing enabled the researchers to interrogate whether regional perfusion differences correspond to specific cell types or neurochemical systems. Therefore, this multiscale analytical framework successfully connected macroscopic hemodynamic signals with microscopic transcriptomic and neuroreceptor landscapes.

Glial and Vascular Signatures in Psychosis Pathophysiology

The study demonstrated compelling spatial alignments between regional perfusion abnormalities and specific non-neuronal gene expression modules. Notably, both established schizophrenia spectrum disorders and the clinical high-risk state shared pronounced associations with genes governing astrocytes, oligodendrocytes, and oligodendrocyte precursor cells. Furthermore, vascular leptomeningeal cells demonstrated significant correlation with perfusion shifts across both stages. These concordant signatures indicate that neurovascular unit impairment and oligodendrocyte-mediated myelination deficits occur early in the disease continuum. However, the investigators also discovered critical stage-specific divergence in glial transcriptomic patterns. In the clinical high-risk cohort, regional cerebral perfusion changes correlated strongly with microglial gene expression modules. This finding highlights early neuroinflammatory activation and stress-response pathways during the prodromal phase. Conversely, individuals with chronic schizophrenia spectrum disorders exhibited significant correlations with endothelial cell gene modules. Consequently, this shift reflects secondary chronic microvascular remodeling and blood-brain barrier dysfunction following persistent psychotic disease. Thus, progressive neuroinflammation appears to transition into established structural vascular changes as psychosis evolves.

Dopaminergic, Cholinergic, and Glutamatergic Receptor Topography

In addition to cellular transcriptomics, the investigators evaluated whether neurotransmitter receptor density patterns could explain regional hemodynamic variations. Dominance analysis demonstrated that normative receptor distributions strongly predicted regional cerebral blood flow differences in both study groups. Remarkably, the neurochemical model accounted for 58% of the variance in schizophrenia spectrum disorders and 60% of the variance in the clinical high-risk cohort. Specifically, dopamine D1 and D2 receptors alongside the dopamine transporter emerged as predominant contributors to perfusion abnormalities. Furthermore, the analysis highlighted critical roles for vesicular acetylcholine transporter and muscarinic M1 receptors, alongside gamma-aminobutyric acid type A and N-methyl-D-aspartate glutamate receptors. These neurochemical associations localized predominantly within subcortical structures, including the striatum, thalamus, and limbic circuits. Because these deep subcortical hubs regulate cognitive filtering and salience attribution, their neurovascular disruption directly mirrors clinical symptom profiles. Therefore, regional hemodynamic changes serve as macroscopic readouts of underlying multi-transmitter dysregulation rather than isolated monoaminergic dysfunction.

Clinical Implications for Early Risk Stratification and Biomarkers

These multiscale findings carry direct clinical relevance for modern neuropsychiatry and early intervention paradigms. Currently, predicting whether a patient at clinical high risk will transition to full psychosis remains challenging. However, identifying distinct microglial and vascular transcriptomic signatures linked to cerebral perfusion offers tangible opportunities for biomarker discovery. Non-invasive arterial spin labeling perfusion magnetic resonance imaging can detect early hemodynamic shifts in symptomatic youth. Moreover, combining perfusion imaging with peripheral inflammatory markers could enhance prognostic stratification in routine psychiatric clinics. For instance, individuals presenting with prominent microglial-linked subcortical hyperperfusion might warrant targeted anti-inflammatory or neuroprotective monitoring. Similarly, observing established endothelial or oligodendrocyte transcriptional signatures could help clinicians identify advanced neurodevelopmental compromise requiring comprehensive psychosocial and pharmacological stabilization. In addition, understanding that regional perfusion mirrors balanced cholinergic, dopaminergic, and glutamatergic signaling prevents over-reliance on simplistic dopaminergic models. Consequently, objective multimodal neuroimaging brings psychiatric practice closer to biologically grounded personalized medicine.

Translational Horizons for Novel Neuroprotective Therapeutics

Beyond diagnostic stratification, these transcriptomic and neurochemical insights outline clear pathways for future pharmacological innovation. Standard antipsychotic medications primarily block dopamine D2 receptors, yet many individuals experience persistent negative and cognitive symptoms. Because this study underscores the significant involvement of muscarinic M1 and N-methyl-D-aspartate receptors, novel pro-cholinergic and glutamatergic modulators gain robust biological validation. Furthermore, identifying active microglial signaling during the clinical high-risk stage suggests an optimal window for anti-inflammatory or immunomodulatory interventions. Administering targeted agents before irreversible endothelial remodeling occurs could prevent microvascular compromise and halt transition toward overt psychosis. Similarly, agents promoting oligodendrocyte survival and remyelination may restore disrupted circuit communication between subcortical nuclei and the cerebral cortex. Therefore, neuroprotective strategies targeting astrocytes, pericytes, and microglia should be tested in prospective prodromal cohorts. Ultimately, translating these multi-scale spatial correlations into clinical therapeutics will help clinicians move beyond symptomatic palliation toward disease-modifying neuropsychiatric care.

How does regional cerebral blood flow correlate with schizophrenia risk?

Regional cerebral blood flow reflects local metabolic and microvascular activity across brain circuits. In individuals at clinical high risk for psychosis, altered subcortical perfusion aligns with microglial gene activity and disrupted neurotransmitter receptor densities, signaling impending network dysfunction before overt clinical psychosis manifests.

Which neurotransmitter systems most strongly predict perfusion changes in psychosis?

Dominance analysis indicates that dopamine D1, D2, and dopamine transporters, along with muscarinic M1 acetylcholine receptors, GABAA, and NMDA glutamate receptors, strongly predict perfusion alterations. Together, these receptors account for nearly sixty percent of regional cerebral blood flow variance in both high-risk and established schizophrenia cohorts.

What distinct cellular signatures differentiate high-risk individuals from established schizophrenia?

While both groups share astrocyte, oligodendrocyte, and vascular leptomeningeal alterations, stage-specific divergence occurs in immunity and vasculature. High-risk individuals demonstrate significant correlation with microglial gene modules reflecting neuroinflammation, whereas chronic schizophrenia spectrum patients exhibit endothelial cell gene correlation representing structural microvascular remodeling and barrier disruption.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of medical conditions. Refer to the latest local and national guidelines for clinical practice.

References

1. Knight SR et al. Transcriptional and Neurochemical Signatures of Cerebral Blood Flow Alterations in Individuals With Schizophrenia or at Clinical High Risk for Psychosis. Biol Psychiatry. 2025 Jul 15. doi: 10.1016/j.biopsych.2025.01.028. PMID: 39923816.


2. Kindler J, Jann K, Homan P, et al. Reduced cortical cerebral blood flow in antipsychotic-free first-episode psychosis and relationship to treatment response. Psychol Med. 2022;52(14):3158-3166. doi: 10.1017/S0033291722002288.


3. Howes OD, McCutcheon R, Owen MJ, Murray RM. The partial dopamine hypothesis of schizophrenia: an update for the 2020s. Annu Rev Med. 2024;75:395-408. doi: 10.1146/annurev-med-042921-124016.


4. Hansen JY, Shafiei G, Markello RD, et al. Mapping neurotransmitter systems to the structural and functional organization of the human brain. Nat Neurosci. 2022;25(11):1569-1581. doi: 10.1038/s41593-022-01186-3.